Immunologic Research

, Volume 48, Issue 1, pp 122–146

Prospects of a novel vaccination strategy for human gamma-herpesviruses


DOI: 10.1007/s12026-010-8172-z

Cite this article as:
Wu, TT., Blackman, M.A. & Sun, R. Immunol Res (2010) 48: 122. doi:10.1007/s12026-010-8172-z


Due to the oncogenic potential associated with persistent infection of human gamma-herpesviruses, including Epstein–Barr virus (EBV or HHV-4) and Kaposi’s sarcoma-associated herpesvirus (KSHV or HHV-8), vaccine development has focused on subunit vaccines. However, the results using an animal model of mouse infection with a related rodent virus, murine gamma-herpesvirus 68 (MHV-68, γHV-68, or MuHV-4), have shown that the only effective vaccination strategy is based on live attenuated viruses, including viruses engineered to be incapable of establishing persistence. Vaccination with a virus lacking persistence would eliminate many potential complications. Progress in understanding persistent infections of EBV and KSHV raises the possibility of engineering a live attenuated virus without persistence. Therefore, we should keep the option open for developing a live EBV or KSHV vaccine.



Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Department of Molecular and Medical Pharmacology, School of MedicineUniversity of California at Los AngelesLos AngelesUSA
  2. 2.Oral Biology, School of DentistryUniversity of California at Los AngelesLos AngelesUSA
  3. 3.The Trudeau InstituteSaranac LakeUSA